{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:27:59Z","timestamp":1787678879694,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-017-0643-2","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T07:53:54Z","timestamp":1515657234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking"],"prefix":"10.1186","volume":"17","author":[{"given":"E.","family":"Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Picatoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Bris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Caro-Vadillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Egido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tu\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-6078","authenticated-orcid":false,"given":"\u00d3.","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"643_CR1","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.","journal-title":"PLoS Med"},{"key":"643_CR2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/0960327112450885","volume":"32","author":"BR Goyal","year":"2013","unstructured":"Goyal BR, Mehta AA. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion. Hum Exp Toxicol. 2013;32:571\u201390.","journal-title":"Hum Exp Toxicol"},{"key":"643_CR3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12933-015-0173-8","volume":"14","author":"J Fuentes-Antr\u00e1s","year":"2015","unstructured":"Fuentes-Antr\u00e1s J, Picatoste B, Ram\u00edrez E, Egido J, Tu\u00f1\u00f3n J, Lorenzo \u00d3. Targeting metabolic disturbance in the diabetic heart. Cardiovasc Diabetol. 2015;14:173.","journal-title":"Cardiovasc Diabetol"},{"key":"643_CR4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1073\/pnas.97.4.1784","volume":"97","author":"YT Zhou","year":"2000","unstructured":"Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA. 2000;97:1784\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"643_CR5","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/01.CIR.103.20.2441","volume":"103","author":"TR Wallhaus","year":"2001","unstructured":"Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441\u20136.","journal-title":"Circulation"},{"key":"643_CR6","doi-asserted-by":"crossref","first-page":"E420","DOI":"10.1152\/ajpendo.2001.280.3.E420","volume":"280","author":"DD Belke","year":"2001","unstructured":"Belke DD, Larsen TS, Gibbs EM, Severson DL. Glucose metabolism in perfused mouse hearts overexpressing human GLUT-4 glucose transporter. Am J Physiol Endocrinol Metab. 2001;280:E420\u20137.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"643_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbrc.2007.01.141","volume":"355","author":"DDJ Habets","year":"2007","unstructured":"Habets DDJ, Coumans WA, Voshol PJ, den Boer MAM, Febbraio M, Bonen A, et al. AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. Biochem Biophys Res Commun. 2007;355:204\u201310.","journal-title":"Biochem Biophys Res Commun"},{"issue":"983\u2013989","key":"643_CR8","first-page":"e7","volume":"166","author":"JB Green","year":"2013","unstructured":"Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(983\u2013989):e7.","journal-title":"Am Heart J"},{"key":"643_CR9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"MH Noyan-Ashraf","year":"2009","unstructured":"Noyan-Ashraf MH, Momen MA, Ban K, Sadi A-M, Zhou Y-Q, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975\u201383.","journal-title":"Diabetes"},{"key":"643_CR10","doi-asserted-by":"crossref","first-page":"e78330","DOI":"10.1371\/journal.pone.0078330","volume":"8","author":"B Picatoste","year":"2013","unstructured":"Picatoste B, Ram\u00edrez E, Caro-Vadillo A, Iborra C, Egido J, Tu\u00f1\u00f3n J, et al. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. potential roles of GLP-1 isoforms. PLoS ONE. 2013;8:e78330.","journal-title":"PLoS ONE"},{"key":"643_CR11","doi-asserted-by":"crossref","first-page":"H1361","DOI":"10.1152\/ajpheart.00885.2010","volume":"300","author":"S Ravassa","year":"2011","unstructured":"Ravassa S, Zudaire A, Carr RD, D\u00edez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol. 2011;300:H1361\u201372.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"643_CR12","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340\u201350.","journal-title":"Circulation"},{"key":"643_CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/00365518709168885","volume":"47","author":"C Orskov","year":"1987","unstructured":"Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165\u201374.","journal-title":"Scand J Clin Lab Invest"},{"key":"643_CR14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1471-2261-14-141","volume":"14","author":"R Li","year":"2014","unstructured":"Li R, Yang J, Yang Y, Ma N, Jiang B, Sun Q, et al. Speckle tracking echocardiography in the diagnosis of early left ventricular systolic dysfunction in type II diabetic mice. BMC Cardiovasc Disord. 2014;14:141.","journal-title":"BMC Cardiovasc Disord"},{"key":"643_CR15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1475-2840-12-172","volume":"12","author":"E Ramirez","year":"2013","unstructured":"Ramirez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Ruperez FJ, et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol. 2013;12:172.","journal-title":"Cardiovasc Diabetol"},{"key":"643_CR16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093\u2013129.","journal-title":"Physiol Rev"},{"key":"643_CR17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/cvr\/cvn116","volume":"79","author":"RW Schwenk","year":"2008","unstructured":"Schwenk RW, Luiken JJFP, Bonen A, Glatz JFC. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008;79:249\u201358.","journal-title":"Cardiovasc Res"},{"key":"643_CR18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207\u201358.","journal-title":"Physiol Rev"},{"key":"643_CR19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.yjmcc.2008.03.021","volume":"44","author":"JA Madrazo","year":"2008","unstructured":"Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol. 2008;44:968\u201375.","journal-title":"J Mol Cell Cardiol"},{"key":"643_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29\u201334.","journal-title":"Am J Cardiol"},{"key":"643_CR21","doi-asserted-by":"crossref","first-page":"e30450","DOI":"10.1371\/journal.pone.0030450","volume":"7","author":"M Eguchi","year":"2012","unstructured":"Eguchi M, Kim YH, Kang KW, Shim CY, Jang Y, Dorval T, et al. Ischemia-reperfusion injury leads to distinct temporal cardiac remodeling in normal versus diabetic mice. PLoS ONE. 2012;7:e30450.","journal-title":"PLoS ONE"},{"key":"643_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1475-2840-8-39","volume":"8","author":"CE Brom van den","year":"2009","unstructured":"van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, et al. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol. 2009;8:39.","journal-title":"Cardiovasc Diabetol"},{"key":"643_CR23","first-page":"689","volume":"47","author":"MJ Welch","year":"2006","unstructured":"Welch MJ, Lewis JS, Kim J, Sharp TL, Dence CS, Gropler RJ, et al. Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study. J Nucl Med. 2006;47:689\u201397.","journal-title":"J Nucl Med"},{"key":"643_CR24","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.108.051672","volume":"49","author":"KI Shoghi","year":"2008","unstructured":"Shoghi KI, Gropler RJ, Sharp T, Herrero P, Fettig N, Su Y, et al. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med. 2008;49:1320\u20137.","journal-title":"J Nucl Med"},{"key":"643_CR25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.numecd.2010.11.006","volume":"21","author":"L Guiducci","year":"2011","unstructured":"Guiducci L, Liistro T, Burchielli S, Panetta D, Bonora D, Di Cecco P, et al. Contribution of organ blood flow, intrinsic tissue clearance and glycaemia to the regulation of glucose use in obese and type 2 diabetic rats: a PET study. Nutr Metab Cardiovasc Dis. 2011;21:726\u201332.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"643_CR26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI60329","volume":"122","author":"PK Battiprolu","year":"2012","unstructured":"Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, Iglewski M, et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest. 2012;122:1109\u201318.","journal-title":"J Clin Invest"},{"key":"643_CR27","doi-asserted-by":"crossref","first-page":"H2106","DOI":"10.1152\/ajpheart.00856.2006","volume":"292","author":"P Yue","year":"2007","unstructured":"Yue P, Arai T, Terashima M, Sheikh AY, Cao F, Charo D, et al. Magnetic resonance imaging of progressive cardiomyopathic changes in the db\/db mouse. Am J Physiol Heart Circ Physiol. 2007;292:H2106\u201318.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"643_CR28","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.109.913350","volume":"122","author":"T Mazzone","year":"2010","unstructured":"Mazzone T. Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. Circulation. 2010;122:2201\u201311.","journal-title":"Circulation"},{"key":"643_CR29","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.12475","volume":"171","author":"N Fillmore","year":"2014","unstructured":"Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2014;171:2080\u201390.","journal-title":"Br J Pharmacol"},{"key":"643_CR30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cardfail.2012.07.009","volume":"18","author":"RM Witteles","year":"2012","unstructured":"Witteles RM, Keu KV, Quon A, Tavana H, Fowler MB. Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail. 2012;18:804\u20139.","journal-title":"J Card Fail"},{"key":"643_CR31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1055\/s-0031-1284383","volume":"43","author":"Y Ishibashi","year":"2011","unstructured":"Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res. 2011;43:731\u20134.","journal-title":"Horm Metab Res"},{"key":"643_CR32","doi-asserted-by":"crossref","unstructured":"Vyas AK, Yang K-C, Woo D, Tzekov A, Kovacs A, Jay PY, et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE. 2011;6. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3040766\/. Accessed 11 Apr 2017.","DOI":"10.1371\/journal.pone.0017178"},{"key":"643_CR33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-10-187","volume":"10","author":"D Linz","year":"2012","unstructured":"Linz D, Hohl M, Mahfoud F, Reil J-C, Linz W, H\u00fcbschle T, et al. Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats. J Transl Med. 2012;10:187.","journal-title":"J Transl Med"},{"key":"643_CR34","doi-asserted-by":"crossref","first-page":"H313","DOI":"10.1152\/ajpheart.2000.279.1.H313","volume":"279","author":"AE Stenbit","year":"2000","unstructured":"Stenbit AE, Katz EB, Chatham JC, Geenen DL, Factor SM, Weiss RG, et al. Preservation of glucose metabolism in hypertrophic GLUT4-null hearts. Am J Physiol Heart Circ Physiol. 2000;279:H313\u20138.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"643_CR35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0022-2828(03)00212-8","volume":"35","author":"MR Morissette","year":"2003","unstructured":"Morissette MR, Howes AL, Zhang T, Heller Brown J. Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2003;35:1217\u201327.","journal-title":"J Mol Cell Cardiol"},{"key":"643_CR36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure\u2014implications beyond ATP production. Circ Res. 2013;113:709\u201324.","journal-title":"Circ Res"},{"key":"643_CR37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/CIRCIMAGING.113.000785","volume":"7","author":"LM McCormick","year":"2014","unstructured":"McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, et al. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease clinical perspective. Circ Cardiovasc Imaging. 2014;7:274\u201381.","journal-title":"Circ Cardiovasc Imaging"},{"key":"643_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","volume":"14","author":"H Oe","year":"2015","unstructured":"Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.","journal-title":"Cardiovasc Diabetol"},{"key":"643_CR39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/HJH.0000000000000886","volume":"34","author":"T Romacho","year":"2016","unstructured":"Romacho T, Vallejo S, Villalobos LA, Wronkowitz N, Indrakusuma I, Sell H, et al. Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release. J Hypertens. 2016;34:869\u201376.","journal-title":"J Hypertens"},{"key":"643_CR40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/JME-11-0127","volume":"48","author":"P Moreno","year":"2012","unstructured":"Moreno P, Nuche-Berenguer B, Guti\u00e9rrez-Rojas I, Acitores A, Sancho V, Valverde I, et al. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states. J Mol Endocrinol. 2012;48:37\u201347.","journal-title":"J Mol Endocrinol"},{"key":"643_CR41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cmet.2007.03.006","volume":"5","author":"S Huang","year":"2007","unstructured":"Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5:237\u201352.","journal-title":"Cell Metab"},{"key":"643_CR42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0014-5793(98)01149-1","volume":"436","author":"P Ebeling","year":"1998","unstructured":"Ebeling P, Koistinen HA, Koivisto VA. Insulin-independent glucose transport regulates insulin sensitivity. FEBS Lett. 1998;436:301\u20133.","journal-title":"FEBS Lett"},{"key":"643_CR43","doi-asserted-by":"crossref","first-page":"37530","DOI":"10.1074\/jbc.M112.363630","volume":"287","author":"RW Schwenk","year":"2012","unstructured":"Schwenk RW, Angin Y, Steinbusch LKM, Dirkx E, Hoebers N, Coumans WA, et al. Overexpression of vesicle-associated membrane protein (VAMP) 3, but not VAMP2, protects glucose transporter (GLUT) 4 protein translocation in an in vitro model of cardiac insulin resistance. J Biol Chem. 2012;287:37530\u20139.","journal-title":"J Biol Chem"},{"key":"643_CR44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tem.2007.02.001","volume":"18","author":"M Armoni","year":"2007","unstructured":"Armoni M, Harel C, Karnieli E. Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation. Trends Endocrinol Metab. 2007;18:100\u20137.","journal-title":"Trends Endocrinol Metab"},{"key":"643_CR45","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1210\/jcem.87.8.8743","volume":"87","author":"JM Egan","year":"2002","unstructured":"Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab. 2002;87:3768\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"643_CR46","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/oby.2008.229","volume":"16","author":"D Elahi","year":"2008","unstructured":"Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring). 2008;16:1501\u20139.","journal-title":"Obesity (Silver Spring)"},{"key":"643_CR47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0030-1253421","volume":"42","author":"E Tomas","year":"2010","unstructured":"Tomas E, Stanojevic V, Habener JF. GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res. 2010;42:657\u201362.","journal-title":"Horm Metab Res"},{"key":"643_CR48","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1463-1326.2010.01345.x","volume":"13","author":"P Anagnostis","year":"2011","unstructured":"Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13:302\u201312.","journal-title":"Diabetes Obes Metab"},{"key":"643_CR49","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/db11-1824","volume":"61","author":"A Mima","year":"2012","unstructured":"Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC\u03b2 activation in diabetes. Diabetes. 2012;61:2967\u201379.","journal-title":"Diabetes"},{"key":"643_CR50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","volume":"3","author":"PA Read","year":"2010","unstructured":"Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195\u2013201.","journal-title":"Circ Cardiovasc Imaging"},{"key":"643_CR51","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","volume":"12","author":"AA Tahrani","year":"2016","unstructured":"Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566\u201392.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-017-0643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T07:54:34Z","timestamp":1515657274000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-017-0643-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1186\/s12933-017-0643-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]},"article-number":"12"}}